Search Results

Aziyo Biologics, Inc. announced a change of the Company’s name to Elutia Inc.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs.

LeMaitre Vascular, Inc., a provider of vascular devices, implants and services, announced it has entered into an agreement with Aziyo Biologics, Inc. to become the exclusive distributor of Aziyo’s cardiovascular patches in the United States.

Aziyo Biologics, Inc., a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, announced it has entered into a distribution agreement with LeMaitre Vascular, Inc., a provider of vascular devices, implants and services.

Perfecting microbial manufacturing processes means taming its greatest asset: speed. This rapid process for creating biologics also means a race against time, where success hinges on conquering three key challenges: designing a robust microbial strain, optimizing fermentation for industrial scale, and ensuring consistent high-yield product yield.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023.

Aziyo Biologics, Inc. and Sientra, Inc. today announced they have entered into an agreement to expand the distribution of Aziyo’s SimpliDerm product line.

Aziyo Biologics, Inc. announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures.

Aziyo Biologics, Inc. provided a business update and reported financial results for the second quarter ended June 30, 2023.